Expression of cancer-testis antigens in lung cancer: definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9

Scanlan M., Altorki N., Gure A. O., Williamson B., Jungbluth A., Chen Y., ...Daha Fazla

CANCER LETTERS, cilt.150, sa.2, ss.155-164, 2000 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 150 Sayı: 2
  • Basım Tarihi: 2000
  • Doi Numarası: 10.1016/s0304-3835(99)00385-7
  • Dergi Adı: CANCER LETTERS
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.155-164
  • Anahtar Kelimeler: cancer testis antigen, BRDT, RING3, bromodomain, cancer vaccine, CYTOLYTIC T-LYMPHOCYTES, TUMOR-ANTIGENS, CANCER/TESTIS ANTIGENS, HUMAN-MELANOMA, DROSOPHILA, IDENTIFICATION, PROTEIN, CELL, REGULATOR
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

In an effort to define new cancer-testis (CT) genes, we investigated whether BRDT, a testis-restricted member of the RING3 family of transcriptional regulators, is also expressed in cancer. Standard RT-PCR expression analysis detected BRDT transcripts in 12 of 47 cases of non-small cell lung cancer and single cases of both squamous cell carcinoma of the head and neck (1/12) and esophagus (1/12) but not in melanoma or in cancers of the colon, breast, kidney and bladder. Typing of 33 non-small cell lung cancers for coexpression of a panel of CT antigens revealed a high incidence (60%) of MAGE-3 mRNA expression, followed by MAGE-1 (36%), CT7/MAGE-C1 (30%), CT10 (30%), SSX4 (23%), BRDT (21%), NY-ESO-1 (21%) and HOM-MEL-40/SSX2 (15%). The coexpression pattern of these antigens provides a foundation for developing a polyvalent lung cancer vaccine. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.